The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial
Open accessAbstract
Importance: Effective treatments for patients with severe COVID-19 are needed. Objective: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. Intervention: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227). Main Outcomes and Measures: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. Results: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. Conclusions and Relevance: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. Trial Registration: ClinicalTrials.gov Identifier: NCT04362813.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Self-citationThe WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Inflammasome formation in the lungs of patients with fatal COVID-19
Toldo, S., Bussani, R., Nuzzi, V., Bonaventura, A., Mauro, A. G., Cannatà, A., Pillappa, R., Sinagra, G., Nana-Sinkam, P., Sime, P., et al. (2021) · Inflammation Research · doi:10.1007/s00011-020-01413-2 · Cited by 132
Self-citationIglesias-Julián, E., López-Veloso, M., de-la-Torre-Ferrera, N., Barraza-Vengoechea, J. C., Delgado-López, P. D., Colazo-Burlato, M., Ubeira-Iglesias, M., Montero-Baladía, M., Lorenzo-Martín, A., Minguito-de-la-Iglesia, J., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102537 · Cited by 62
Cited by
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Kyriazopoulou, E., Poulakou, G., Milionis, H., Metallidis, S., Adamis, G., Tsiakos, K., Fragkou, A., Rapti, A., Damoulari, C., Fantoni, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01499-z · Cited by 536
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Self-citationA guide to immunotherapy for COVID-19
van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01643-9 · Cited by 320
Metadata
- Authors
- Caricchio, R., Abbate, A., Gordeev, I., Meng, J., Hsue, P. Y., Neogi, T., Arduino, R., Fomina, D., Bogdanov, R., Stepanenko, T., Ruiz-Seco, P., Gónzalez-García, A., Chen, Y., Li, Y., Whelan, S., Noviello, S., CAN-COVID Investigators, Faguer, S., Papi, A., Di Marco, F., Agafina, A. S., Mochalova, A. S., Lioznov, D. A., Privalov, D. V., Trufanov, K. V., Martynenko, T. I., Pablos-Alvarez, J. L., Bujan, S., Estrada, V., Solanich-Moreno, X., Randeva, H., Tahir, H., Lachmann, H. J., Savic, S., Patel, V., Lachiewicz, A., Taiwo, B., Kuritzkes, D. R., Jacobson, J. M., Chua, J. V., Shirinian, M., Fung, M., Overton, T., Malhotra, V., Kissin, E., Morone, N., Sagar, M., Trojanowski, M., Desai, P., Krachman, S., Salerno, D., Stewart, J., Zheng, M., Gupta, R., Shenoy, K., Marchetti, N., Patel, M., Jaffe, F., Chowdhury, J., Brown, J., Vega-Sanchez, M. E., Codella, S., Verga, S., Fernandez-Romero, G., Mokha, J., Criner, G. J., Rali, P., Sehgal, S., Dorey-Stein, Z., Satti, A., Dominguez-Castillo, E., Mills, N., Mamary, A. J., Gangemi, A., Shani, J., Frankel, R., Sharma, K., Malyshev, Y., Brady, J., Christian, M., Tan-Augenstein, G., Chiandussi, D. A., Behne, A., Black, M., Bonaventura, A., Earl Clary, R., Deutsch, H., Duke, C., Greer, J., Hardin, M., Harmon, M., Kemp, H., Ho, A.-C., Ibe, I., Ladd, A., Marawan, A., Markley, R., McKee, K., Mihalick, V., Montpetit, A., Mbualungu, J., O’Brien, J., Owen, C., Pak, M., Patel, N., Payne, W., Priday, A., Sculthorpe, R., Sears, M., Sedhai, Y. R., Sims, E. K., Spence, K., Tackett, H., Thomas, G., Turner, J., Van Tassell, B., Vecchiè, A., & Wohlford, G.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-07-20
- Volume
- 326
- Issue
- 3
- Pages
- 230
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3183356099
- Cited by
- 164
- References
- 5
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2021.9508
- The paper
- Caricchio, R., Abbate, A., Gordeev, I., Meng, J., Hsue, P. Y., Neogi, T., Arduino, R., Fomina, D., Bogdanov, R., Stepanenko, T., Ruiz-Seco, P., Gónzalez-García, A., Chen, Y., Li, Y., Whelan, S., Noviello, S., CAN-COVID Investigators, Faguer, S., Papi, A., . . . Wohlford, G. (2021). Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2021.9508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.